| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥2.5B | ¥6.5B | -61.3% |
| Operating Income | ¥-9.5B | ¥-7.4B | -28.7% |
| Ordinary Income | ¥-9.4B | ¥-7.2B | -30.5% |
| Net Income | ¥-20.1B | ¥-7.3B | -177.4% |
| ROE | -132.4% | -21.2% | - |
FY2026 Q3 results show severe deterioration with Revenue 2.5B yen (YoY -61.3%), Operating Income -9.5B yen (YoY -28.7% worsening from -7.4B yen loss), Ordinary Income -9.4B yen (YoY -30.5% worsening from -7.2B yen loss), and Net Income -20.1B yen (YoY -177.4% worsening from -7.3B yen loss). The company operates in diamond single crystal manufacturing, sales and development as a single segment business. Gross profit margin collapsed to -135.1% as cost of sales reached 6.0B yen against revenue of only 2.5B yen, while SG&A expenses remained elevated at 6.1B yen. A large impairment loss of 10.7B yen in extraordinary items was a major contributor to the expanded net loss. Cash and deposits declined sharply by 73.1% YoY from 14.4B yen to 3.9B yen, raising liquidity concerns. Total equity decreased from 34.2B yen to 15.2B yen as retained earnings deteriorated to -30.0B yen. The company projects full-year revenue of 5.0B yen with net loss of -19.8B yen and zero dividend.
Revenue declined 61.3% YoY to 2.5B yen, reflecting sharp contraction in core diamond single crystal business demand. The company operates as a single segment in diamond single crystal manufacturing, sales and development, thus the revenue decline represents weakness across the entire business model. Cost of sales at 6.0B yen exceeded revenue, resulting in negative gross profit of -3.4B yen and gross margin of -135.1%, indicating severe manufacturing cost structure issues and under-absorption of fixed costs due to low production volumes. SG&A expenses remained at 6.1B yen (242.1% of revenue), demonstrating significant operating leverage deterioration as fixed costs were not adjusted in line with revenue contraction. Operating loss expanded to -9.5B yen from -7.4B yen YoY, worsening by 28.7%. Non-operating income provided a small positive contribution of approximately 0.1B yen, narrowing ordinary loss slightly to -9.4B yen. The gap between ordinary income of -9.4B yen and net income of -20.1B yen is attributable to extraordinary losses including impairment charges of 10.7B yen, representing non-recurring factors that significantly amplified the bottom-line loss. The impairment likely relates to property, plant and equipment revaluation given the 10.0B yen decline in tangible fixed assets on the balance sheet. This represents a revenue down and profit down pattern, with both top-line and bottom-line deteriorating substantially, exacerbated by structural cost issues and large one-time asset write-downs.
[Profitability] ROE of -132.4% reflects severe capital erosion from accumulated losses, operating margin of -377.1% indicates fundamental operational unprofitability with costs far exceeding revenue generation capacity. Net profit margin of -795.2% substantially underperforms the manufacturing industry median of 6.5%, ranking at the bottom of peer distribution. [Cash Quality] Cash and deposits stand at 3.9B yen, down 10.6B yen or 73.1% YoY, providing 1.14 times coverage of current liabilities at 3.4B yen, indicating adequate but diminishing short-term liquidity buffer. Interest coverage ratio is deeply negative at -166.38, meaning operating income cannot cover interest expenses, raising debt servicing sustainability concerns. [Investment Efficiency] Asset turnover of 0.107 is substantially below the manufacturing industry median of 0.56, reflecting very low revenue generation relative to asset base. Inventory turnover deteriorated to 299 days versus industry median of 112 days, with work-in-process accumulating to 6.6B yen indicating manufacturing bottlenecks. Cash conversion cycle extended to 766 days from 388 days, driven by inventory build-up and operational inefficiency. [Financial Health] Equity ratio of 64.1% appears healthy on surface, though equity base declined from 34.2B yen to 15.2B yen due to loss accumulation. Current ratio of 518.6% and quick ratio of 376.2% suggest strong liquidity ratios, but quality is questioned given inventory composition and cash depletion. Debt-to-equity ratio of 0.56 and financial leverage of 1.56 are moderate, with long-term debt at 3.6B yen comprising 15.3% of total liabilities and equity.
Cash and deposits decreased sharply by 10.6B yen or 73.1% YoY to 3.9B yen, reflecting significant cash consumption during the period. Operating losses of 9.5B yen combined with working capital deterioration driven by inventory accumulation of 1.0B yen to 4.9B yen total (with work-in-process reaching 6.6B yen) constrained cash generation from operations. The substantial decline in property, plant and equipment by 10.0B yen to 5.5B yen, coupled with impairment losses of 10.7B yen recorded in the income statement, indicates asset disposal or write-downs that did not generate offsetting cash inflows sufficient to stabilize liquidity. Accounts receivable decreased 0.7B yen to 0.5B yen in line with revenue contraction, providing some working capital relief. Accounts payable increased 0.2B yen to 0.3B yen, suggesting extended payment terms with suppliers contributing modestly to cash preservation. Retained earnings deteriorated by 20.1B yen to -30.0B yen, consistent with the net loss. Current liabilities of 3.4B yen remain manageable relative to current assets of 17.7B yen, though the cash-to-current-liabilities ratio declined to 1.14 from a stronger historical position. The combination of operating cash consumption, asset base contraction, and limited financing activities resulted in material erosion of the cash buffer, elevating liquidity risk for near-term obligations and operational funding requirements.
Ordinary income of -9.4B yen versus operating income of -9.5B yen shows non-operating net contribution of approximately 0.1B yen, comprising primarily interest and dividend income with minimal financial income contribution. Non-operating income represents approximately 4% of revenue at 0.1B yen, a negligible factor given the revenue scale. The substantial divergence between ordinary income of -9.4B yen and net income of -20.1B yen is driven by extraordinary losses totaling approximately 10.7B yen, primarily from impairment charges on fixed assets. These impairment losses represent non-recurring factors that significantly distort underlying operational performance assessment. Excluding the 10.7B yen impairment, recurring loss would approximate -9.4B yen at the ordinary income level, still reflecting severe operational unprofitability. Earnings quality is compromised by the negative gross margin structure where cost of sales exceeds revenue, indicating fundamental business model stress rather than temporary margin pressure. The persistence of large SG&A expenses at 6.1B yen against minimal revenue demonstrates high fixed cost burden and limited cost flexibility. Operating cash flow data is not disclosed in the quarterly statement, preventing direct assessment of cash earnings quality. However, the 10.6B yen decline in cash combined with operating losses and inventory accumulation suggests weak cash conversion. Accruals assessment indicates deterioration, with large non-cash charges (impairment) and working capital build-up (inventory) consuming resources without corresponding revenue or cash generation, signaling low earnings quality and sustainability concerns.
Full-year guidance projects revenue of 5.0B yen, operating loss of -9.2B yen, ordinary loss of -9.1B yen, and net loss of -19.8B yen with EPS forecast of -136.00 yen and zero dividend. Q3 cumulative results show revenue progress rate of 50.6% (2.5B yen / 5.0B yen), aligned with the standard 75% benchmark for Q3, indicating Q4 revenue of 2.5B yen is assumed, matching Q1-Q3 cumulative level. Operating loss progress rate is 103.6% (-9.5B yen / -9.2B yen forecast), exceeding full-year guidance, suggesting slight improvement or lower loss is expected in Q4. Net loss progress rate is 101.5% (-20.1B yen / -19.8B yen forecast), also exceeding full-year guidance, with the Q3 impairment of 10.7B yen constituting the bulk of expected annual extraordinary losses. The guidance implies Q4 revenue recovery to approximately 2.5B yen to achieve the 5.0B yen annual target, requiring substantial sequential improvement from the depressed Q1-Q3 run rate. However, given persistent negative gross margins and high fixed costs, achieving even break-even operations in Q4 appears challenging. The forecast assumes no significant additional impairments beyond those already recorded. Order backlog data is not disclosed, limiting visibility into forward revenue pipeline and demand recovery prospects. The absence of positive guidance revision despite Q3 completion suggests management maintains cautious outlook amid continued operational difficulties.
Annual dividend is zero yen with no interim or year-end dividend declared, unchanged from prior guidance. Given net loss of -20.1B yen and negative retained earnings of -30.0B yen, dividend payments are not feasible under current financial condition. Payout ratio is not calculable due to negative earnings. No share buyback activities are disclosed. Total shareholder return ratio is zero as neither dividends nor buybacks are implemented. The company's dividend policy reflects financial distress and capital preservation priority. Restoration of dividend payments would require return to profitability, rebuilding of retained earnings, and establishment of sustainable cash generation capacity, none of which are evident in the current trajectory or near-term guidance.
Revenue contraction risk remains elevated as sales declined 61.3% YoY to 2.5B yen with full-year guidance implying limited recovery, indicating weak demand for diamond single crystal products and uncertain market outlook requiring close monitoring of order intake and customer activity levels. Liquidity and cash burn risk intensified as cash and deposits decreased 73.1% to 3.9B yen while operating losses continue at 9.5B yen for nine months, with current monthly burn rate threatening to exhaust cash reserves absent revenue recovery or external financing, requiring quarterly cash position tracking and potential capital raise evaluation. Inventory obsolescence and asset impairment risk persists with work-in-process at 6.6B yen and finished goods at 4.9B yen representing 299 days of inventory turnover, combined with 10.7B yen impairment already recorded, suggesting further write-down exposure if demand remains weak or manufacturing efficiency fails to improve, necessitating inventory aging analysis and production rationalization.
[Industry Position] (Reference - Proprietary Analysis) The company's financial metrics fall substantially below manufacturing sector norms across all key dimensions. Profitability metrics show ROE of -132.4% versus industry median of 5.8%, operating margin of -377.1% versus industry median of 8.9%, and net profit margin of -795.2% versus industry median of 6.5%, placing the company in severe financial distress relative to peers. Revenue growth of -61.3% YoY significantly underperforms industry median growth of 2.8% (IQR: -1.5% to 8.8%), indicating company-specific demand or execution challenges beyond sector trends. Financial health indicators show equity ratio of 64.1% slightly above industry median of 63.8%, though the absolute equity base has eroded substantially. Current ratio of 518.6% exceeds industry median of 2.87x, but this is offset by poor asset quality with inventory turnover at 299 days versus industry median of 112 days, and operating working capital cycle of 766 days implied versus industry median of 112 days, indicating severe working capital inefficiency. Asset turnover of 0.107 trails industry median of 0.56 by a wide margin, reflecting very low revenue productivity of asset base. The company's financial leverage of 1.56 is close to industry median of 1.53, suggesting moderate debt usage, but negative interest coverage makes this leverage unsustainable. Overall, the company ranks at or near the bottom quartile of manufacturing sector peers across profitability, growth, and efficiency metrics, with only static balance sheet ratios appearing comparable, reflecting a business in fundamental distress requiring comprehensive operational restructuring and potential recapitalization. (Industry: Manufacturing, N=105 companies, Comparison: 2025-Q3 period, Source: Proprietary analysis)
The earnings data reveals a company in acute financial distress characterized by collapsing revenue (down 61.3% YoY), deeply negative operating margins (-377.1%), and accelerating cash consumption (cash down 73.1%) that raise going-concern considerations. The 10.7B yen impairment charge and severe working capital deterioration (inventory days at 299, cash conversion cycle at 766 days) indicate fundamental business model challenges beyond cyclical factors, requiring monitoring of management's restructuring plans including cost reduction execution, inventory liquidation progress, and potential asset or business divestitures. Near-term catalysts to watch include Q4 revenue achievement versus the 2.5B yen implied target to meet full-year guidance, any announcements regarding additional financing or capital raises to address the depleted 3.9B yen cash position, and operational metrics on manufacturing efficiency improvements to reverse negative gross margins, with current trajectory suggesting heightened financial risk absent significant operational turnaround or external capital infusion.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.